GliomaLoG-GlioNCT02686229
Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas
An observational study of Glioma, run by University of Ulm at 1 site in Germany.
Trial summary
The LoG-Glio-Registry is based on a network of german hospitals gathering radiological, clinical, epidemiological and molecular data on all patients diagnosed with a low grade glioma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioma
- How many people
- 300 participants
- Where
- 1 siteGermany
- Study dates
- 15 Nov 2015to Dec 2036
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All adult patients with radiological suspected diagnosis of a low grade glioma
Who may be able to join
- Patients with radiological suspected diagnosis of a low grade glioma
- Age ≥ 18 years. There is no upper age limit.
Who cannot join
- Severe neurological or psychiatric disorder interfering with ability to give an informed consent
- No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation
- No consent for bio-banking of patient's biological specimens and performance of analyses on stored material.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University of Ulm
Ulm
Jan Coburger, MD, jan.coburger@uni-ulm.de
About this study
Official title: Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas: The LOG-Glio-Project
The LoG-Glio-Registry is based on a network of german hospitals gathering radiological, clinical, epidemiological and molecular data on all patients diagnosed with a low grade glioma.
- Conditions
- Glioma
- Being tested
- no interventions
- Keywords
- Low grade glioma, registry, neurosurgery, brain tumor
- Medical subject headings
- Glioma, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
no interventionsOther
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free survival (PFS)
Measured: 5yrs
Overall survival (OS)
Measured: 15yrs
Secondary outcomes (2)
Extent of tumor resection
calculated based on volumetric assessement of tumor in cm³ and residual tumor in pre and postoperative MRI
Measured: 3yrs
Quality of life (QoL) assessed by the EORTC QLQ C-30/BN-20. (European Organisation for Research and Treatment of Cancer Quality of Life Questionaire C-30
Measured: 5yrs
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2016 (estimated)
- Study start15 Nov 2015
- Primary completion31 Dec 2026 (estimated)
- Study completionDec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GliomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- University of Ulm
- Sponsor type
- University, hospital or other
- Collaborators
- Charite University, Berlin, Germany
- Responsible party
- Principal investigator, Jan Coburger, University of Ulm
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02686229
- Sponsor's protocol ID
- LoG-Glio
- Acronym
- LoG-Glio
- Status last verified
- May 2023
- First submitted
- 4 Feb 2016
- Last updated
- 11 May 2023
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Pala A, Nadji-Ohl M, Faust K, Ruckriegel S, Roder C, von der Brelie C, Forster MT, Lobel F, Schommer S, Lohr M, Renovanz M, Grubel N, Rothenbacher D, Konig R, Engelke J, Schmitz B, Wirtz CR, Ringel F, Senft C, Rohde V, Tatagiba M, Ernestus RI, Vajkoczy P, Ganslandt O, Nagel G, Coburger J. Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project. J Neurol Surg A Cent Eur Neurosurg. 2020 Jan;81(1):48-57. doi: 10.1055/s-0039-1693650. Epub 2019 Sep 24.
PubMed 31550737